Quick Answer
Sionna Therapeutics, Inc. reported Research And Development Expense of $60.26 million for the year ending 2025.
- Sionna Therapeutics, Inc. showed an increase of +5.2% in Research And Development Expense from 2024 to 2025.
- This data is from Sionna Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 2, 2026.
- XBRL data for this metric is available from 2024 to 2025 (2 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2024: $10.22 million | Q2 2024: $8.23 million | Q3 2024: $24.58 million | Q1 2025: $13.67 million | Q2 2025: $15.38 million | Q3 2025: $16.04 million.
- Historical annual values: Fiscal year 2025: $60.26 million | Fiscal year 2024: $57.29 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: